160 related articles for article (PubMed ID: 19177205)
21. Silencing of LIM and SH3 Protein 1 (LASP-1) Inhibits Thyroid Cancer Cell Proliferation and Invasion.
Gao W; Han J
Oncol Res; 2017 Jul; 25(6):879-886. PubMed ID: 27938497
[TBL] [Abstract][Full Text] [Related]
22. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma.
Zhang H; Li Z; Chu B; Zhang F; Zhang Y; Ke F; Chen Y; Xu Y; Liu S; Zhao S; Liang H; Weng M; Wu X; Li M; Wu W; Quan Z; Liu Y; Zhang Y; Gong W
Tumour Biol; 2016 Jun; 37(6):8305-15. PubMed ID: 26729195
[TBL] [Abstract][Full Text] [Related]
23. Lasp-1 regulates podosome function.
Stölting M; Wiesner C; van Vliet V; Butt E; Pavenstädt H; Linder S; Kremerskothen J
PLoS One; 2012; 7(4):e35340. PubMed ID: 22514729
[TBL] [Abstract][Full Text] [Related]
24. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
25. LASP-1, a novel urinary marker for detection of bladder cancer.
Ardelt P; Grünemay N; Strehl A; Jilg C; Miernik A; Kneitz B; Butt E
Urol Oncol; 2013 Nov; 31(8):1591-8. PubMed ID: 22481019
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Itoh T; Hayashi Y; Kanamaru T; Morita Y; Suzuki S; Wang W; Zhou L; Rui JA; Yamamoto M; Kuroda Y; Itoh H
J Gastroenterol Hepatol; 2000 Apr; 15(4):422-30. PubMed ID: 10824888
[TBL] [Abstract][Full Text] [Related]
27. Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer.
Frietsch JJ; Grunewald TG; Jasper S; Kammerer U; Herterich S; Kapp M; Honig A; Butt E
Br J Cancer; 2010 May; 102(11):1645-53. PubMed ID: 20461080
[TBL] [Abstract][Full Text] [Related]
28. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
[TBL] [Abstract][Full Text] [Related]
29. Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1.
Zhao L; Wang H; Liu C; Liu Y; Wang X; Wang S; Sun X; Li J; Deng Y; Jiang Y; Ding Y
Gut; 2010 Sep; 59(9):1226-35. PubMed ID: 20660701
[TBL] [Abstract][Full Text] [Related]
30. Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms.
Jin Y; Liang ZY; Zhou WX; Zhou L
Hepatol Int; 2019 Mar; 13(2):180-189. PubMed ID: 30600477
[TBL] [Abstract][Full Text] [Related]
31. Suppression of LASP-1 attenuates the carcinogenesis of prostatic cancer cell lines: Key role of the NF-κB pathway.
Sun W; Guo L; Shao G; Liu X; Guan Y; Su L; Zhao S
Oncol Rep; 2017 Jan; 37(1):341-347. PubMed ID: 27840958
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of LIM and SH3 Protein 1 leading to accelerated G2/M phase transition contributes to enhanced tumourigenesis in oral cancer.
Shimizu F; Shiiba M; Ogawara K; Kimura R; Minakawa Y; Baba T; Yokota S; Nakashima D; Higo M; Kasamatsu A; Sakamoto Y; Tanzawa H; Uzawa K
PLoS One; 2013; 8(12):e83187. PubMed ID: 24386158
[TBL] [Abstract][Full Text] [Related]
33. Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
Paland N; Gamliel-Lazarovich A; Coleman R; Fuhrman B
Atherosclerosis; 2014 Nov; 237(1):200-7. PubMed ID: 25244504
[TBL] [Abstract][Full Text] [Related]
34. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
Zhou L; Hayashi Y; Itoh T; Wang W; Rui J; Itoh H
Pathol Int; 2000 May; 50(5):392-7. PubMed ID: 10849328
[TBL] [Abstract][Full Text] [Related]
35. Nuclear import of LASP-1 is regulated by phosphorylation and dynamic protein-protein interactions.
Mihlan S; Reiß C; Thalheimer P; Herterich S; Gaetzner S; Kremerskothen J; Pavenstädt HJ; Lewandrowski U; Sickmann A; Butt E
Oncogene; 2013 Apr; 32(16):2107-13. PubMed ID: 22665060
[TBL] [Abstract][Full Text] [Related]
36. The LIM and SH3 domain protein family: structural proteins or signal transducers or both?
Grunewald TG; Butt E
Mol Cancer; 2008 Apr; 7():31. PubMed ID: 18419822
[TBL] [Abstract][Full Text] [Related]
37. [Impact of LASP-1 expression on proliferation and tumorigenesis of human colorectal cancer cell line SW480].
Zhao L; Ding YQ
Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):830-4. PubMed ID: 21215099
[TBL] [Abstract][Full Text] [Related]
38. Moscatilin Inhibits Metastatic Behavior of Human Hepatocellular Carcinoma Cells: A Crucial Role of uPA Suppression via Akt/NF-κB-Dependent Pathway.
Yu CL; Weng MS; Chen WC; Chien KT; Chi CW; Chung CH; Huang CW; Wang PC; Chen CC; Tsai AC; Liu SC; Wang SW
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805784
[TBL] [Abstract][Full Text] [Related]
39. Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma.
Liu W; Xu G; Ma J; Jia W; Li J; Chen K; Wang W; Hao C; Wang Y; Wang X
Tohoku J Exp Med; 2011 May; 224(1):29-39. PubMed ID: 21512310
[TBL] [Abstract][Full Text] [Related]
40. Investigating lasp-2 in cell adhesion: new binding partners and roles in motility.
Bliss KT; Chu M; Jones-Weinert CM; Gregorio CC
Mol Biol Cell; 2013 Apr; 24(7):995-1006. PubMed ID: 23389630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
